10-Q: Organon & Co. Q1 2026 Earnings: Revenue Dip, Strategic Divestiture

Organon & Co. reported a 4% decrease in Q1 2026 revenue to $1.46 billion, impacted by lower sales of key products, while also announcing a significant divestiture and a proposed acquisition.

Summary

• Organon & Co. reported first-quarter 2026 revenues of $1.46 billion, a 4% decrease compared to $1.51 billion in the first quarter of 2025.
• The decrease in revenue was primarily attributed to lower sales of Nexplanon/Implanon NXT, Singulair, Marvelon/Mercilon, and Ontruzant.
• The company completed the divestiture of the Jada System in January 2026, recognizing a net gain of $81 million.
• Restructuring costs were $31 million in Q1 2026, down from $86 million in Q1 2025, related to headcount reductions and operational optimization.
• Net income for the quarter was $146 million, or $0.55 per diluted share, compared to $87 million, or $0.33 per diluted share, in the prior year.
• Organon entered into an exclusive license agreement for global rights to Miudella, a hormone-free copper IUD.
• The company announced a definitive agreement to be acquired by Sun Pharmaceutical Industries Limited for $14.00 per share in cash, expected to close in early 2027.
• Material weaknesses in internal control over financial reporting persist, related to tone at the top and information/communication, with ongoing remediation efforts.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as slightly negative due to the revenue decline and persistent internal control weaknesses, although positives like increased net income and a significant divestiture gain offer some mitigation.

Positives

• Net income increased to $146 million in Q1 2026 from $87 million in Q1 2025.
• Diluted EPS rose to $0.55 in Q1 2026 from $0.33 in Q1 2025.
• The divestiture of the Jada System resulted in an $81 million net gain.
• Sales of Emgality increased by 69% (50% excluding foreign exchange).
• Hadlima sales increased by 44% (43% excluding foreign exchange).
• Atozet sales increased by 11% (5% excluding foreign exchange).
• The company entered into a license agreement for Miudella, a hormone-free IUD.
• Cash and cash equivalents increased significantly to $1.116 billion from $574 million at the end of 2025.

Negatives

• Worldwide sales decreased by 4% to $1.46 billion in Q1 2026 compared to $1.51 billion in Q1 2025.
• Nexplanon/Implanon NXT sales declined 19% (21% excluding foreign exchange) due to decreased physician demand in the U.S. and timing of shipments internationally.
• Singulair sales declined 46% (49% excluding foreign exchange) due to less favorable medical guidelines, supply constraints, and price reductions.
• Ontruzant sales declined 71% (72% excluding foreign exchange) due to increased competition and lower tendered volume.
• Material weaknesses in internal control over financial reporting persist.
• The company is subject to ongoing litigation, including product liability and securities class actions.

Risks

• The proposed merger with Sun Pharmaceutical Industries Limited is subject to closing conditions, including regulatory approvals and stockholder approval, and may not be completed.
• Failure to complete the merger could adversely affect the stock price, future business, and financial results, potentially impacting the ability to continue as a going concern.
• The company faces ongoing litigation, including product liability lawsuits related to Fosamax and Nexplanon/Implanon, and securities and stockholder derivative lawsuits.
• Material weaknesses in internal control over financial reporting persist, increasing the risk of misstatements in financial reports.
• Competition from generic products and loss of market exclusivity for key products pose ongoing risks.
• Changes in U.S. and foreign government laws and regulations, including pricing pressures and reimbursement policies, could adversely affect business.
• Cyberattacks or failures of IT systems could disrupt operations.
• The company is subject to clawback policies related to incentive compensation.

Future Outlook

The company expects to continue adapting its business and sales strategies to address changing market conditions, including ongoing conflicts, tariffs, tax law changes, and regulatory uncertainty. Volume-based procurement in China is expected to continue negatively impacting the general medicines product portfolio for the next several quarters. The acquisition by Sun Pharma is expected to close in early 2027, subject to customary closing conditions.

Management Comments

• Organon & Co. is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day.
• The company is committed to taking steps necessary to remediate the material weaknesses in internal control over financial reporting.
• Senior leadership has disseminated Company-wide and team-specific communications to emphasize commitment to core values, compliance, integrity, and ethics.

Industry Context

StockSavvy.ai notes that Organon's Q1 2026 results reflect ongoing challenges in the pharmaceutical sector, including increased competition, pricing pressures, and the impact of regulatory changes. The proposed acquisition by Sun Pharma suggests a strategic shift, potentially driven by the need for scale or a change in market dynamics.

Comparison to Industry Standards

• Organon's revenue decline of 4% in Q1 2026, while concerning, is within the range experienced by some pharmaceutical companies facing patent expirations and generic competition. For instance, companies like Pfizer and Merck have also reported revenue fluctuations due to similar factors.
• The increase in net income and EPS, despite revenue decline, suggests effective cost management and a favorable product mix or one-time gains, a strategy often employed by mature pharmaceutical companies to maintain profitability.
• The company's focus on women's health and biosimilars aligns with growing market segments. However, competition in the biosimilar space is intensifying, with companies like Amgen and Biogen also investing heavily in this area.
• The ongoing remediation of material weaknesses in internal controls is a critical area for Organon. Industry best practices emphasize robust internal controls to ensure financial reporting accuracy and investor confidence, a standard that Organon is actively working to meet.

Management Changes

Corporate Governance

Legal Proceedings

• Merck is a defendant in product liability lawsuits in the U.S. involving Fosamax, alleging femur fractures and other bone injuries. Master Settlement Agreements have been entered into for New Jersey and California cases.
• Merck is a defendant in lawsuits relating to Nexplanon and Implanon, alleging various injuries. A Master Settlement Agreement was signed for most of these cases.
• A stockholder filed a lawsuit alleging materially false and misleading statements regarding the company's capital allocation and debt reduction strategies. Two such class actions have been consolidated.
• Two stockholder derivative lawsuits allege breach of fiduciary duties arising from purportedly false and misleading statements.
• Organon made a voluntary self-disclosure to the SEC regarding an investigation into the company's Nexplanon sales to certain wholesalers in the United States.
• Organon received a Paragraph IV Certification Letter from Xiromed Pharma Espana, S.L. regarding an ANDA for a generic version of Nexplanon, triggering a patent infringement lawsuit.
• Various other pending legal proceedings, principally product liability and intellectual property lawsuits, are considered not material individually or in aggregate.

Related Party Transactions

• The company manufactures certain products for Merck, or its applicable affiliate, and Merck manufactures certain products for the company, or its applicable affiliate, under manufacturing and supply agreements.
• Amounts due from Merck were $158 million as of March 31, 2026, and amounts due to Merck were $350 million as of March 31, 2026.

Stakeholder Impact

• Shareholders: The proposed acquisition by Sun Pharma at $14.00 per share in cash provides a potential exit for shareholders, subject to closing conditions. Persistent internal control weaknesses and ongoing litigation could impact share price.
• Employees: Restructuring initiatives resulted in a 3% headcount reduction in Q1 2026. Employee retention may be challenging due to uncertainty surrounding the pending merger.
• Customers: The company continues to adapt sales strategies, which may include product discount programs. Changes in market conditions and regulatory uncertainty could affect product access and demand.
• Suppliers: The company is continuing to separate its supply chain through planned exits from supply agreements with Merck, which may impact supplier relationships and sourcing strategies.
• Creditors: The company has significant long-term debt, and the successful completion of the merger or alternative financing will be crucial for repayment of maturing debt.

Next Steps

• Complete the acquisition by Sun Pharmaceutical Industries Limited, expected in early 2027.
• Continue remediation efforts for material weaknesses in internal control over financial reporting.
• Launch Vtama in certain international markets in 2026 and beyond, subject to regulatory approvals.
• Assess the future commercial launch of Poherdy (pertuzumab) in the U.S.
• Continue to adapt business and sales strategies to address changing market conditions.

Key Dates

Recommendation

Organon's Q1 2026 results show a revenue decline, but net income and EPS improved due to cost management and a one-time gain from divestiture. The persistent internal control weaknesses are a concern. However, the definitive agreement to be acquired by Sun Pharma at a premium provides a clear path for shareholders, making 'hold' appropriate pending the transaction's closing, while acknowledging the risks associated with its completion.

Keywords

Organon & Co., Form 10-Q, Quarterly Report, Financial Statements, Revenue, Net Income, Earnings Per Share, Restructuring, Divestiture, Acquisition, Merger, Sun Pharmaceutical Industries, Nexplanon, Jada System, Biosimilars, Womens Health, General Medicines